Skip to main content
. 2022 Feb 18;40(15):1671–1680. doi: 10.1200/JCO.21.02188

FIG 1.

FIG 1.

Percentage change from baseline in (A) spleen volume and (B) TSS at week 24 and (C) BMF improvement from baseline at any time on study. aPatients with nonmissing percent change from baseline at week 24. BMF, bone marrow fibrosis; SV, spleen volume; SVR35, spleen volume reduction of ≥ 35%; TSS, total symptom score; TSS50, ≥ 50% reduction in total symptom score.